---

Notes: Fetal Erythropoiesis, Hemoglobin Development, Blood Group Transfusion Reactions, TACO & TRALI

---

1. FETAL ERYTHROPOIESIS

Phase 1 - Mesoblastic / Yolk Sac Phase (up to ~6 weeks)

• The earliest blood cells are produced in the yolk sac, approximately 15 days after fertilization
• Islands of cells (blood islands) form within the yolk sac; some differentiate into primitive blood cells called hemocytoblasts
• The endothelium of blood vessels and mesenchyme also begin contributing around the 4th week of gestation
• Red cells at this stage are nucleated megaloblasts (large, nucleated, hence called "blasts")
• This mesoblastic phase ends by ~6 weeks' gestation

Phase 2 - Hepatic / Hepato-splenic Phase (6 weeks to ~7 months)

• After 6 weeks, erythropoiesis shifts to the liver (primary site), with the spleen contributing to a lesser extent
• The liver and spleen are the dominant sites of fetal erythropoiesis through most of intrauterine life
• The bone marrow, spleen, and lymphoid tissues begin RBC production near the end of the first trimester
• Red cells gradually shift from nucleated to non-nucleated forms as gestation progresses

Phase 3 - Myeloid / Bone Marrow Phase (last trimester onward)

• In the last few weeks before birth, the bone marrow begins producing RBCs
• By 8 to 10 weeks after birth, the bone marrow is the sole site of erythrocyte production
• All other organ systems gradually lose their erythropoietic capacity

Key Features of Fetal RBCs

• Early fetal RBCs are nucleated; non-nucleated cells increase as gestation advances
• Reticulocyte count is high in the young fetus but decreases to ~5% at term (adults: <1%)
• RBC life span in a term fetus is ~80 days (vs. 120 days in adults); shorter in premature infants
• Hemoglobin concentration rises to ~15 g/dL by midgestation and ~17 g/dL at term

---

2. HEMOGLOBIN DEVELOPMENT

Globin Gene Clusters

• Alpha-like chains (ζ and α) are encoded by genes on chromosome 16
• Beta-like chains (ε, γ, δ, β) are encoded by genes on chromosome 11
• A locus control region (LCR) regulates expression of β-like chains during development
• Gene expression shifts sequentially with the site of erythropoiesis

Embryonic Hemoglobins (Yolk Sac Phase - 1st trimester only)

• ζ and ε chain synthesis ceases by 8 weeks' gestation
• These are of little clinical importance in laboratory medicine

Fetal Hemoglobin - HbF (α₂γ₂)

• Production begins when erythropoiesis shifts to the liver and spleen (~6-8 weeks)
• HbF is the predominant hemoglobin of fetal life
• HbF synthesis is particularly prominent from 11 weeks postconception through birth
• Small amounts of HbA (α₂β₂) are also produced during fetal life (<10%)
• At birth: ~75% HbF, ~25% HbA
• By 1 year: HbF <1% (adult levels)

Why HbF Has Higher O₂ Affinity Than HbA

• HbF has higher oxygen affinity due to special properties of γ-chains
• 2,3-DPG (2,3-diphosphoglycerate) binds to β-chains of HbA but does NOT bind HbF, so cannot reduce HbF's O₂ affinity
• This allows oxygen to transfer from maternal HbA → diffuses into chorionic villi → binds fetal HbF at the placenta

The Hemoglobin Switch (HbF → HbA)

• A developmentally programmed switch controlled by transcription factors
• HbF predominates until ~38 weeks when the switch to HbA begins
• Postnatally, HbF production rapidly falls; HbA and HbA₂ (α₂δ₂) replace it
• By 12 months, adult pattern is fully established

Adult Hemoglobins

Hereditary Persistence of Fetal Hemoglobin (HPFH)

• Some clinically normal individuals produce abnormally high levels (up to 100%) of HbF in place of HbA postnatally
• Caused by point mutations in γ-globin promoters (non-deletion HPFH) or deletions removing δ and β genes (deletion HPFH)
• Clinically beneficial in sickle cell disease and β-thalassemia - elevated HbF ameliorates severity
• One major research goal: pharmacologically reactivate γ-globin transcription (e.g., hydroxyurea works partly via this mechanism)

---

3. BLOOD GROUP TRANSFUSION REACTIONS

ABO Blood Group System

• ABO antigens are expressed on RBC surfaces; "natural" (pre-formed) IgM antibodies against A and B antigens are present without prior transfusion exposure
• ABO incompatibility is the most common cause of fatal transfusion reactions - usually from patient misidentification at the bedside

Types of Transfusion Reactions

A. Acute Hemolytic Transfusion Reaction (AHTR)

• Cause: Pre-formed IgM antibodies (usually anti-A or anti-B) binding donor RBCs → complement activation → intravascular hemolysis
• Most common cause: ABO-incompatible transfusion due to clerical/identification error
• Symptoms: Fever, shaking chills, flank/back pain, hemoglobinuria (red/brown urine), hypotension
• Signs: Positive direct Coombs test (unless all donor RBCs already lysed), hemoglobinemia, hemoglobinuria
• Complications: Can rapidly progress to DIC, shock, renal failure, death
• Note: Complement activation causes the symptoms, not just hemolysis itself - osmotic lysis alone (e.g., RBCs in 5% dextrose) causes hemoglobinuria without systemic symptoms
• Management: Stop transfusion immediately, IV fluids, monitor renal function, treat DIC if present

B. Delayed Hemolytic Transfusion Reaction (DHTR)

• Cause: IgG antibodies against RBC antigens (Rh, Kell, Kidd, Duffy systems) formed from prior transfusion/pregnancy exposure - antibody undetectable at pre-transfusion testing, then anamnestic rise post-transfusion
• Mechanism: Typically extravascular hemolysis - IgG-opsonized donor RBCs phagocytosed by reticuloendothelial system
• Timing: Days to weeks after transfusion
• Symptoms: Mild fever, falling hemoglobin, jaundice - usually less dramatic than AHTR
• Lab: Positive direct Coombs, low haptoglobin, elevated LDH, indirect hyperbilirubinemia
• Some antibodies (Rh, Kell, Kidd) can fix complement → severe reactions similar to ABO mismatch
• Also includes Delayed Serologic Transfusion Reaction (DSTR) - alloantibody develops but without hemolysis

C. Febrile Non-Hemolytic Transfusion Reaction (FNHTR)

• Common; caused by cytokines from donor leukocytes or recipient antibodies against donor leukocytes
• Fever (≥1°C rise), chills during transfusion - must rule out hemolytic reaction and infection
• Treated with antipyretics; prevented by leukoreduction

D. Allergic Reactions

• Mild (urticarial): IgE-mediated response to allergens in donor plasma; occurs in 1-3% of transfusions; manageable with antihistamines, transfusion can often be restarted
• Severe (anaphylactic): Most likely in patients with IgA deficiency (prevalence 1:300-1:500); recipient has IgG anti-IgA antibodies that react with IgA in donor product; incidence ~1 in 20,000-50,000 transfusions
  • Treatment: Stop transfusion, IM epinephrine (adrenaline), IV chlorpheniramine, IV hydrocortisone
  • Future transfusions: use IgA-deficient blood products or washed RBCs

---

4. TACO - Transfusion-Associated Circulatory Overload

Definition

Epidemiology

• The #1 leading cause of transfusion-related mortality in the United States
• Occurs in 1-12% of transfused patients (variation based on definitions and surveillance)
• More common in: elderly patients, ICU patients, those receiving multiple units over short periods

Risk Factors

• Advanced age, female sex, white race
• Small body weight/stature
• Pre-existing cardiac, renal, or pulmonary disease
• Positive fluid balance

• Large volume transfusions over short time
• Rapid rate of infusion
• Multiple units transfused

Pathophysiology

• Transfusion → hypervolemia → elevated hydrostatic pressure → cardiogenic pulmonary edema (transudative)
• Inflammation and altered endothelial activation may also contribute (beyond pure volume effect)

Clinical Features

• Timing: Acute or worsening pulmonary edema within 6-12 hours of transfusion
• Dyspnea, tachycardia, hypertension (distinguishes from TRALI)
• Positive fluid balance
• Chest X-ray: bilateral pulmonary edema with enlarged cardiac silhouette (cardiomegaly)
• Elevated BNP / NT-proBNP

Treatment

1. Stop transfusion immediately
2. Sit patient upright
3. High-flow oxygen
4. Diuretics (furosemide) - key differentiating point from TRALI management
5. Supportive care

Prevention

• Careful risk assessment before transfusion
• Single-unit transfusions in small/frail adults
• Slow transfusion rates
• Co-administration of diuretics in high-risk patients
• Avoid unnecessary transfusions

---

5. TRALI - Transfusion-Related Acute Lung Injury

Definition

Epidemiology

• Incidence: <1 per 10,000 transfusions (low but serious)
• Historically the most common cause of severe morbidity/mortality after transfusion
• Most commonly associated with: platelets, FFP (fresh frozen plasma), and increasingly now - red blood cells (after donor deferral policies reduced plasma-related TRALI)
• Mortality: ~5% in uncomplicated cases; up to 67% in severely ill patients

Pathophysiology - "Two-Hit Hypothesis"

• Hit 1 (Recipient/Patient): The recipient's clinical condition "primes" neutrophils for activation
  • Priming causes: sepsis, shock, smoking, surgery, major trauma
  • Primed neutrophils become sequestered in pulmonary microvasculature
• Hit 2 (Transfused Product): A factor in the transfused blood product activates these primed neutrophils
  • Most common factor: Anti-HLA antibodies (particularly anti-MHC class I antibodies) in donor plasma
  • Also: Anti-human neutrophil antigen (HNA) antibodies, bioactive lipids (lysophosphatidylcholine), CD40 ligand
  • These antibodies react with recipient's neutrophils, monocytes, and pulmonary endothelium
  • Result: Neutrophil degranulation → endothelial damage → capillary leak → non-cardiogenic pulmonary edema (ARDS-like picture)

Source of Donor Antibodies

• Anti-HLA antibodies are most commonly found in multiparous women (sensitized to paternal MHC antigens expressed by the fetus during pregnancy)
• Measures to exclude multiparous female donors from plasma donation have substantially reduced TRALI incidence
  • Rates fell from 2.57 → 0.81 per 10,000 transfused units after implementing male-only plasma in some centers

Clinical Features

• Timing: Sudden onset within 1-6 hours of transfusion (usually 1-2 hours)
• Respiratory distress, tachypnea, tachycardia, fever
• Hypotension (vs. hypertension in TACO)
• Pink frothy secretions (high albumin - increased permeability edema)
• ~70% require mechanical ventilation

Radiology

• Bilateral alveolar opacities (bilateral infiltrates)
• Normal cardiac silhouette (no cardiomegaly - key distinction from TACO)
• No pleural effusion
• Resolves within 4 days in most cases

Diagnosis

• Clinical: new acute hypoxia + bilateral infiltrates within 6 hours of transfusion, without pre-existing ALI, circulatory overload, or other cause
• Detection of granulocyte, leukoagglutinating, or lymphotoxic antibodies in donor or recipient serum (not always found)
• BNP levels: Low/normal in TRALI; elevated in TACO - useful differentiating tool

Treatment

• Supportive - stop transfusion immediately
• High-flow oxygen
• Mechanical ventilation if required (lung-protective ventilation strategy as in ARDS)
• No role for corticosteroids (no convincing evidence)
• Patient should not receive further products from the implicated donor

TACO vs. TRALI - Key Comparison Table

---

Quick Summary Mnemonics

• Yolk sac → Liver & spleen → Marrow (Bone marrow) = YLM

• Portland (ζ₂γ₂), Gower-1 (ζ₂ε₂), Gower-2 (α₂ε₂)